Nuvectis Pharma Inc (NVCT NASDAQ) stock market data APIs
$8.3198
-0.07(-0.8%)
as of July 15, 2025
Try our APIs with
free plan!
Nuvectis Pharma Inc Financial Data Overview
Price chart is built with
Anychart
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trial for the treatment of patients with platinum-resistant ARID1a-mutated ovarian carcinoma. The company is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Prev. Close
8.3198
Open
8.2492
High
8.441
Low
8.1281
52 wk Range
4.44-11.8
Market Cap
172 M
Shares Outstanding
20 894 K
EPS
0.27
Beta
-0.163
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Nuvectis Pharma Inc data using free add-ons & libraries
Get Nuvectis Pharma Inc Fundamental Data
Nuvectis Pharma Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-06
- EPS/Forecast: -0.26
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Nuvectis Pharma Inc News
New
Nuvectis Pharma (NVCT) ten percent owner buys $269k in stock
Charles Mosseri Marlio, a ten percent owner of Nuvectis Pharma , Inc. (NASDAQ:NVCT), has recently purchased a significant amount of the company’s stock. According to a Form 4 filing with the Securi...
Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference
Fort Lee, NJ, May 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative...
Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights
NXP900 clinical data presentation from the Phase 1a dose escalation study at the 2025 American Association for Cancer Research (AACR) conference demonstrated robust pharmacodynamic response and accept...
Why Nuvectis Pharma, Inc. (NVCT) is Surging in 2025
We recently published a list of Why These 15 Healthcare Stocks Are Surging in 2025. In this article, we are going to take a look at where Nuvectis Pharma Inc (NASDAQ:NVCT) stands against other healthc...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
